Proteo Inc Quick Ratio (PTEO) starting from the first quarter 2020 to first quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Proteo Inc  (PTEO)

Proteo Inc's Quick Ratio

PTEO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Proteo Inc's Cash & cash equivalent grew by 186.21 % in the Q1 2020 sequentially, faster than Current Liabilities, this led to improvement in Proteo Inc's Quick Ratio to 2.23, above Proteo Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 319 other companies have achieved higher Quick Ratio than Proteo Inc in first quarter 2020. While Quick Ratio total ranking in the first quarter 2020 has deteriorated compared to the prior quarter from 1003 to 1182.

Explain Quick Ratio?
How much Cash & cash equivalents PTEO´s has?
What are PTEO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTEO Quick Ratio (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1
Y / Y Current Liabilities Change -21.98 % -13.85 % -12.28 % -60.32 % -49.15 %
Y / Y Cash & cash equivalent Change 149.29 % 11.68 % 7.77 % -31.47 % 3.98 %
Quick Ratio MRQ 2.23 0.91 1.62 1.17 0.7
PTEO's Total Ranking # 1182 # 1003 # 1264 # 1336 # 2318
Seq. Current Liabilities Change 16.53 % 34.64 % -22.03 % -36.22 % 28.68 %
Seq. Cash & cash equivalent Change 186.21 % -24.71 % 8.5 % 6.62 % 28.22 %



Quick Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 320
Healthcare Sector # 526
Overall Market # 1182


Quick Ratio Statistics
High Average Low
5.38 1.07 0.34
(Mar 31 2014)   (Mar 31 2018)




Financial Statements
Proteo Inc's Current Liabilities $ 0 Millions Visit PTEO's Balance sheet
Proteo Inc's Cash & cash equivalent $ 0 Millions Visit PTEO's Balance sheet
Source of PTEO's Sales Visit PTEO's Sales by Geography


Cumulative Proteo Inc's Quick Ratio

PTEO's Quick Ratio for the trailling 12 Months

PTEO Quick Ratio

 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth -34.58 % -42.97 % -51.51 % -59.61 % -49.5 %
Y / Y Cash & cash equivalent TTM Growth 26.71 % -6.34 % -12.75 % -15.08 % 0.11 %
Quick Ratio TTM 1.51 1.02 0.96 0.92 0.78
Total Ranking TTM # 4852 # 4521 # 4901 # 4927 # 1230
Seq. Current Liabilities TTM Growth -7.84 % -3.7 % -2.34 % -24.54 % -19.65 %
Seq. Cash & cash equivalent TTM Growth 36.46 % 2.28 % 2.13 % -11.11 % 0.88 %

Quick ratio ranking by company, industry and sector >> Back to PTEO Financial Strength Comparisons >> Go to Compare PTEO Quick Ratio to its Competitors

On the trailing twelve months basis PTEO Cash & cash equivalent more than doubled by 149.29 % in Q1 2020 year on year, while Current Liabilities increased to $0 millions, this led to increase in in Proteo Inc's Quick Ratio to 1.51, above PTEO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 491 other companies have achieved higher Quick Ratio than Proteo Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2019 from 4521 to 4852.

Explain Quick Ratio?
How much Cash & cash equivalents PTEO´s has?
What are PTEO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 492
Healthcare Sector # 950
Within the Market # 4852


trailing twelve months Quick Ratio Statistics
High Average Low
1.51 0.73 0.38
(Mar 31 2020)   (Mar 31 2018)




Companies with similar Quick Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2020 MRQ Cash & cash equivalentMar 31 2020 MRQ Current Liabilities
Odonate Therapeutics Inc   6.11 $ 153.117  Millions$ 25.044  Millions
Eton Pharmaceuticals Inc   6.01 $ 12.335  Millions$ 2.051  Millions
Insmed Inc  6.00 $ 428.942  Millions$ 71.532  Millions
Otonomy Inc   5.98 $ 48.606  Millions$ 8.124  Millions
Travere Therapeutics Inc   5.94 $ 356.460  Millions$ 59.991  Millions
Tempest Therapeutics Inc   5.94 $ 58.007  Millions$ 9.769  Millions
Chiasma Inc   5.91 $ 79.262  Millions$ 13.404  Millions
Zynerba Pharmaceuticals Inc   5.91 $ 60.639  Millions$ 10.258  Millions
Galmed Pharmaceuticals Ltd   5.88 $ 47.079  Millions$ 8.012  Millions
Cyclerion Therapeutics Inc   5.87 $ 67.096  Millions$ 11.435  Millions
Corvus Pharmaceuticals Inc   5.87 $ 68.707  Millions$ 11.712  Millions
Bio Green Med Solution Inc   5.86 $ 8.923  Millions$ 1.523  Millions
Ovid Therapeutics Inc   5.85 $ 58.487  Millions$ 9.992  Millions
Morphic Holding inc   5.79 $ 219.012  Millions$ 37.833  Millions
Arca Biopharma Inc  5.78 $ 6.674  Millions$ 1.155  Millions
Catalyst Pharmaceuticals Inc   5.77 $ 101.751  Millions$ 17.636  Millions
Arrowhead Pharmaceuticals Inc   5.77 $ 307.610  Millions$ 53.334  Millions
Carisma Therapeutics Inc   5.76 $ 42.463  Millions$ 7.366  Millions
Notable Labs Ltd   5.76 $ 42.980  Millions$ 7.459  Millions
Fulcrum Therapeutics Inc   5.73 $ 81.207  Millions$ 14.182  Millions
Mustang Bio inc   5.71 $ 55.814  Millions$ 9.778  Millions
Quoin Pharmaceuticals Ltd   5.68 $ 5.277  Millions$ 0.929  Millions
Rafael Holdings Inc  5.68 $ 8.430  Millions$ 1.485  Millions
Oramed Pharmaceuticals Inc  5.65 $ 28.926  Millions$ 5.123  Millions
Cti Biopharma Corp   5.63 $ 81.149  Millions$ 14.405  Millions
Chinook Therapeutics Inc   5.61 $ 130.521  Millions$ 23.264  Millions
Tricida Inc   5.57 $ 284.293  Millions$ 51.057  Millions
Merrimack Pharmaceuticals Inc  5.47 $ 18.025  Millions$ 3.296  Millions
Evelo Biosciences Inc   5.45 $ 58.115  Millions$ 10.657  Millions
Xeris Biopharma Holdings Inc   5.44 $ 96.942  Millions$ 17.825  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.